Shares of Rezolute, Inc. (NASDAQ:RZLT – Get Free Report) have been assigned a consensus rating of “Buy” from the eight analysts that are presently covering the stock, Marketbeat reports. Eight equities research analysts have rated the stock with a buy rating. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $24.13.
RZLT has been the subject of several analyst reports. JMP Securities reiterated a “market outperform” rating and set a $7.00 price objective on shares of Rezolute in a report on Friday, September 20th. Wedbush reiterated an “outperform” rating and issued a $112.00 price target on shares of Rezolute in a research note on Monday, November 4th. Finally, HC Wainwright restated a “buy” rating and set a $14.00 price target on shares of Rezolute in a research note on Friday, November 8th.
Read Our Latest Analysis on Rezolute
Insider Activity
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Affinity Asset Advisors LLC raised its stake in shares of Rezolute by 15.6% during the 2nd quarter. Affinity Asset Advisors LLC now owns 1,850,000 shares of the company’s stock valued at $7,955,000 after buying an additional 250,000 shares during the last quarter. Marshall Wace LLP acquired a new stake in Rezolute during the second quarter worth about $4,503,000. Geode Capital Management LLC raised its position in Rezolute by 39.0% during the third quarter. Geode Capital Management LLC now owns 491,601 shares of the company’s stock valued at $2,385,000 after acquiring an additional 137,905 shares in the last quarter. Exome Asset Management LLC lifted its holdings in Rezolute by 24.7% in the third quarter. Exome Asset Management LLC now owns 352,056 shares of the company’s stock valued at $1,707,000 after acquiring an additional 69,656 shares during the period. Finally, Acadian Asset Management LLC boosted its position in Rezolute by 104.2% in the 2nd quarter. Acadian Asset Management LLC now owns 184,502 shares of the company’s stock worth $792,000 after purchasing an additional 94,156 shares in the last quarter. 82.97% of the stock is currently owned by institutional investors and hedge funds.
Rezolute Stock Down 0.6 %
NASDAQ:RZLT opened at $4.72 on Wednesday. The stock has a market capitalization of $273.49 million, a price-to-earnings ratio of -3.72 and a beta of 1.08. Rezolute has a 52 week low of $0.90 and a 52 week high of $6.19. The firm has a 50 day moving average of $5.00 and a 200 day moving average of $4.83.
About Rezolute
Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
Featured Articles
- Five stocks we like better than Rezolute
- How to Calculate Options Profits
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- Insider Trades May Not Tell You What You Think
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- 10 Best Airline Stocks to Buy
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Rezolute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rezolute and related companies with MarketBeat.com's FREE daily email newsletter.